Brilinta 90mg Tablet

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Product photography not yet supplied — this space will show official packaging imagery once provided by the business.

Product Overview

Brilinta 90 mg Tablet contains ticagrelor, a P2Y12 platelet inhibitor (antiplatelet). It is prescribed to help prevent heart attack and stroke in patients with heart disease — including after a recent heart attack or episode of severe, heart-related chest pain — by reducing the formation of harmful blood clots in the blood vessels.

Active ingredient
Ticagrelor
Strength
90 mg
Dosage form
Oral tablet
Therapeutic class
P2Y12 platelet inhibitor (antiplatelet)
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with ticagrelor and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Prevention of heart attack and stroke in patients with heart disease
  • Use following a recent heart attack or unstable angina
  • Described as helping blood circulate more freely by reducing harmful clot formation
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Swallowed whole, with or without food, at a fixed time each day
  • Usually taken together with low-dose aspirin, as directed by the prescriber
  • Treatment should not be stopped even when feeling well; the prescribed course should be completed

Described Side Effects

Commonly described side effects include:

  • Bleeding (e.g. bruising, nosebleeds)
  • Breathlessness (dyspnoea)

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • Increased bleeding risk; any unusual or prolonged bleeding should be reported promptly
  • Not recommended in patients with liver disease, or during pregnancy or breastfeeding, per manufacturer guidance
  • The prescriber should be told before any surgery or dental procedure
  • Full medical history and all current medicines should be shared with the prescriber

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling, ticagrelor is an antiplatelet used to help prevent heart attack and stroke in patients with heart disease, including after a recent heart attack or unstable angina. SDO Pharma has not independently verified these claims.

Swallowed whole at a fixed time each day, usually with low-dose aspirin, at the dose and duration set by the prescriber.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services